Selective availability of IL-2 is a major determinant controlling the production of CD4+CD25+Foxp3+ T regulatory cells

被引:48
|
作者
Yu, Aixin [1 ]
Malek, Thomas R. [1 ]
机构
[1] Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33101 USA
来源
JOURNAL OF IMMUNOLOGY | 2006年 / 177卷 / 08期
关键词
D O I
10.4049/jimmunol.177.8.5115
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The development and maintenance of T regulatory (Treg) cells critically depend on IL-2. This requirement for IL-2 might be due to specificity associated with IL-2R signal transduction or because IL-2 was uniquely present in the niche in which Treg cells reside. To address this issue, we examined the capacity of IL-7R-dependent signaling to support Treg cell production and prevent autoimmunity in IL-2R beta(-/-) mice. Expression of transgenic wild-type IL-7R or a chimeric receptor that consisted of the extracytoplasmic domain of the IL-7R alpha-chain and the cytoplasmic domain of IL-2R beta-chain in IL-2R beta(-/-) mice did not prevent autoimmunity. Importantly, expression of a chimeric receptor that consisted of the extracytoplasmic domain of the IL-2R beta-chain and the cytoplasmic domain of IL-7R alpha-chain in IL-2R beta-t- mice led to Treg cells production in the thymus and periphery and prevented autoimmunity. Signaling through the IL-2R or chimeric IL-2R beta/IL-7R alpha in vivo or the culture of thymocytes from IL-2R beta(-/-) mice with IL-7 led to up-regulation of Foxp3 and CD25 on Treg cells. These findings indicate that IL-7R signal transduction is competent to promote Treg cell production, but this signaling requires triggering through IL-2 by binding to the extracytoplasmic portion of the IL-2R via this chimeric receptor. Thus, a major factor controlling the nonredundant activity of the IL-2R is selective compartmentalization of IL-2-producing cells with Treg cells in vivo.
引用
收藏
页码:5115 / 5121
页数:7
相关论文
共 50 条
  • [1] IL-2 signaling and CD4+CD25+Foxp3+ regulatory T cells
    Turka, Laurence A.
    Walsh, Patrick T.
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2008, 13 : 1440 - 1446
  • [2] IL-2 induces in vivo suppression by CD4+CD25+Foxp3+ regulatory T cells
    Brandenburg, Susan
    Takahashi, Takeshi
    de la Rosa, Maurus
    Janke, Marko
    Karsten, Gabriele
    Muzzulini, Till
    Orinska, Zane
    Bulfone-Paus, Silvia
    Scheffold, Alexander
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2008, 38 (06) : 1643 - 1653
  • [3] IL-2/anti-IL-2 complexes ameliorate lupus nephritis by expansion of CD4+CD25+Foxp3+ regulatory T cells
    Yan, Ji-Jing
    Lee, Jae-Ghi
    Jang, Joon Young
    Koo, Tai Yeon
    Ahn, Curie
    Yang, Jaeseok
    KIDNEY INTERNATIONAL, 2017, 91 (03) : 603 - 615
  • [4] CD4+CD25+FoxP3+ regulatory T cells in autoimmune diseases
    Xavier Valencia
    Peter E Lipsky
    Nature Clinical Practice Rheumatology, 2007, 3 : 619 - 626
  • [5] A function for IL-7R for CD4+CD25+Foxp3+ T regulatory cells
    Bayer, Allison L.
    Lee, Joon Youb
    de la Barrera, Anabel
    Surh, Charles D.
    Malek, Thomas R.
    JOURNAL OF IMMUNOLOGY, 2008, 181 (01): : 225 - 234
  • [6] 4-1BB Signaling in Conventional T Cells Drives IL-2 Production That Overcomes CD4+CD25+FoxP3+ T Regulatory Cell Suppression
    Barsoumian, Hampartsoum B.
    Yolcu, Esma S.
    Shirwan, Haval
    PLOS ONE, 2016, 11 (04):
  • [7] Characterization of CD4+CD25+foxp3+ regulatory T cells in psoriatic skin
    Gyulai, R.
    Kocsis, K.
    Varga, B.
    Kemény, L.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 : 49 - 49
  • [8] Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells
    Battaglia, M
    Stabilini, A
    Roncarolo, MG
    BLOOD, 2005, 105 (12) : 4743 - 4748
  • [9] The lifestyle of naturally occurring CD4+CD25+Foxp3+ regulatory T cells
    Shevach, Ethan M.
    DiPaolo, Richard A.
    Andersson, John
    Zhao, Dong-Mei
    Stephens, Geoffrey L.
    Thornton, Angela M.
    IMMUNOLOGICAL REVIEWS, 2006, 212 : 60 - 73
  • [10] CD4+CD25+Foxp3+ T cells and CD4+CD25-Foxp3+ T cells in aged mice
    Nishioka, T.
    Iida, R.
    Shimizu, J.
    JOURNAL OF NEUROIMMUNOLOGY, 2006, 178 : 147 - 147